Treatment of cartilage disorders with FGF-18
This invention concerns the treatment of cartilage disorder and osteoarthritis in particular. More specifically, it relates to the use of FGF-18 in treatment regimens of patients having a cartilage disorder such as osteoarthritis, such as for example knee osteoarthritis or secondary hip osteoarthritis. Specifically provided is a preferred treatment scheme comprising once weekly administration of an FGF-18 compound per treatment cycle.
1. A method for treating a patient having a cartilage disorder characterized by cartilage injury or a loss of cartilage in a joint comprising the intraarticular administration of an FGF-18 compound to a mammalian patient having a cartilage disorder, wherein the FGF-18 compound is administered in a treatment cycle that comprises the administration of said FGF-18 compound at least three times and each administration is separated by at least 6 days, wherein said FGF-18 compound is intraarticularly administered into a joint in which cartilage has been lost or injured and said treatment results in an increase in cartilage deposition in said joint of said mammalian patient, and wherein said FGF-18 compound comprises amino acid residues 28 to 207 of SEQ ID NO: 2 or SEQ ID NO: 5 (FGF-18 (170AA)).
2. The method according to claim 1 , wherein each administration is separated by 7 days.
3. The method according to claim 1 , wherein said treatment cycle comprises the administration of said FGF-18 compound once per week for at least 3 consecutive weeks.
4. The method according to claim 1 , wherein said treatment cycle comprises the administration of said FGF-18 compound once per week for 3 consecutive weeks.
5. The method according to claim 1 , wherein treatment cycles are repeated 2, 4, 6 or 8 months after the first administration of said FGF-18 compound.
6. The method according to claim 1 , said method comprising 1, 2, 3, 4, 5 or 6 treatment cycles per year.
7. The method according to claim 1 , said method comprising the administration of said FGF-18 compound at a dose of: 3-100 mcg; 5-40 mcg; or 10-30 mcg per single intra-articular administration.
8. The method according to claim 7 , said method comprising the administration of said FGF-18 compound at a dose of 3-100 mcg per single intra-articular administration.
9. The method according to claim 7 , said method comprising the administration of said FGF-18 compound at a dose of 5-40 mcg per single intra-articular administration.
10. The method according to claim 7 , said method comprising the administration of said FGF-18 compound at a dose of 10-30 mcg per single intra-articular administration.
11. The method according to claim 1 , said method comprising the administration of said FGF-18 compound at a dose of about 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 mcg per single intra-articular administration.
12. The method according to claim 1 , wherein the FGF-18 compound comprises SEQ ID NO: 5 (FGF-18(170AA)).
13. The method according to claim 1 , wherein said administrations are separated by 6 days.
14. The method according to claim 1 , wherein said administrations are separated by 8 days.
15. The method according to claim 1 , wherein said treatment cycle comprises the administration of said FGF-18 compound once per week for 4 consecutive weeks.
16. A method of treating a patient having cartilage injury comprising administering a FGF-18 compound to a mammalian patient having a cartilage injury, wherein said FGF-18 compound is administered intraarticularly in a treatment cycle that comprises the administration of said FGF-18 compound at least three times and each administration is separated by at least 6 days and said treatment increases cartilage deposition in a joint of said mammalian patient, and wherein said FGF-18 compound comprises amino acid residues 28 to 207 of SEQ ID NO: 2 or SEQ ID NO: 5 (FGF-18 (170AA)).
17. The method according to claim 16 , wherein said FGF-18 compound is administered in a treatment cycle that comprises the administration of said FGF-18 compound once per week for 3 consecutive weeks.
18. The method according to claim 17 , wherein said FGF -18 compound comprises amino acid residues 28-207 of SEQ ID NO: 2.
19. The method according to claim 17 , wherein said FGF-18 compound comprises SEQ ID NO: 5 (FGF-18(170AA)).
20. The method according to claim 16 , wherein said FGF-18 compound is administered in a treatment cycle that comprises the administration of said FGF-18 compound once per week for 4 consecutive weeks.
21. The method according to claim 16 , wherein said FGF-18 compound comprises amino acid residues 28-207 of SEQ ID NO: 2.
22. The method according to claim 16 , wherein said FGF-18 compound comprises SEQ ID NO: 5 (FGF-18(170AA)).
23. The method according to claim 16 , wherein treatment cycles are repeated 2, 4, 6, or 8 months after the first administration of said FGF-18 compound.
24. The method according to claim 16 , said method comprising 1, 2, 3, 4, 5, or 6 treatment cycles per year.
25. A method for treating a patient having osteoarthritis comprising the intraarticular administration of an FGF-18 compound comprising amino acid residues 28 to 207 of SEQ ID NO: 2 or SEQ ID NO: 5 (FGF-18 (170AA)) into an osteoarthritic joint of a mammalian patient, wherein the FGF-18 compound is administered in a treatment cycle that comprises the administration of said FGF-18 compound at least three times, each administration is separated by at least 6 days and treatment results in an increase in cartilage deposition in said osteoarthritic joint.
26. The method according to claim 25 , wherein the osteoarthritis is knee osteoarthritis or hip osteoarthritis or secondary hip osteoarthritis.
27. The method according to claim 25 , wherein said FGF-18 compound is administered in a treatment cycle that comprises the administration of said FGF-18 compound once per week for 3 consecutive weeks.
28. The method according to claim 25 , wherein said FGF-18 compound is administered in a treatment cycle that comprises the administration of said FGF-18 compound once per week for 4 consecutive weeks.
29. The method according to claim 28 , wherein said FGF-18 compound comprises amino acid residues 28-207 of SEQ ID NO: 2.
30. The method according to claim 28 , wherein said FGF-18 compound comprises SEQ ID NO: 5 (FGF-18(170AA)).
31. The method according to claim 25 , wherein said FGF-18 compound comprises amino acid residues 28-207 of SEQ ID NO: 2.
32. The method according to claim 25 , wherein said FGF-18 compound comprises SEQ ID NO: 5 (FGF-18(170AA)).
33. The method according to claim 25 , wherein treatment cycles are repeated 2, 4, 6 or 8 months after the first administration of said FGF-18 compound.
34. The method according to claim 25 , said method comprising 1, 2, 3, 4, 5 or 6 treatment cycles per year.